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Calmodulin is a prevalent calcium sensing protein found in all cells. Three genes exist for
calmodulin and all three of these genes encode for the exact same protein sequence. Recently
mutations in the amino acid sequence of calmodulin have been identified in living human
patients. Thus far, patients harboring these mutations in the calmodulin sequence have only
displayed an altered cardiac related phenotype. Calcineurin is involved in many key
physiological processes and its activity is regulated by calcium and calmodulin. In order to
assess whether or not calcineurin contributes to calmodulinopathy (a pathological state arising
from dysfunctional calmodulin), a comprehensive search of relevant literature has been
performed. Herein, the physiological roles of calcineurin and consequences of dysfunction have
been reviewed for literature focused on the heart.
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CHAPTER I
AN OVERVIEW OF CARDIAC PHYSIOLOGY
1.1

General mechanisms of heart function.
The heart is essential for human life. Dysfunction of the heart can reduce blood flow

throughout the body, which will impair delivery of nutrients such as oxygen. Notably, loss of
oxygen to the brain can result in irreversible damage within five minutes and fatality in
approximately ten minutes. The heart is comprised of four main chambers, two atria and two
ventricles. The ventricles are responsible for generating the force that pumps the blood
throughout the body. The atria serve to refill the ventricle after they are depleted. The timing of
atrial and ventricular contractions are governed by electrical currents that are generated by ion
channel proteins contained in specialized cells throughout the heart. Dysfunction or loss of
function to these ion channels can alter or disrupt the timing or contractile properties of the
different chambers in the heart 1.
1.2

An overview of excitation-contraction coupling.
Ion channels function by allowing ions to pass across a cellular membrane. Some ion

channels allow ions to flow into the cell, while others allow passage out of the cell. Ions flow
through the ion channels due to differences in ion concentration between the inside and outside
of cells. When ions pass through the membrane this alters the electrical potential on the
membrane surface. In the specialized muscle cells, known as cardiomyocytes, electrical currents
are used to manipulate the concentration of calcium inside the cardiomyocyte. This mechanism is
1

referred to as excitation contraction coupling. Briefly, in response to membrane depolarization
voltage-gated sodium channels open. Further depolarization is achieved by opening of the
voltage-sensitive calcium channels, which allows Ca2+ ions to flow into the cell. This influx of
calcium triggers calcium-induced calcium release from the sarcoplasmic reticulum through the
intracellular Ca2+ ion channel referred to as ryanodine receptor type II. The resulting effect is an
elevation of intracellular [Ca2+] from 100 nM to approximately 1 μM. Changes in intracellular
[Ca2+] primarily do three things inside the cell. First, an increase in [Ca2+] alters the
conformation of troponin C. Restructuring the troponin complexes allosterically moves
tropomyosin out of the way so the myosin and actin proteins are able to interact. Myosin utilizes
ATP to generate a pulling force along actin. Cooperativity between the sarcomeric proteins and
cardiomyocytes generate the necessary force required for heart contraction. Cardiac contraction
can be enhanced by increasing the amplitude of calcium transient, or changes in [Ca2+], inside a
cardiomyocyte. This allows for a greater population of myosin to engage actin and thereby
generates a larger force. In a typical human resting heart approximately 30% of myosin is used to
engage actin and generate the force for contraction. This allows the heart to have a tunable range
to support extra physical exertion when needed 2.
1.3

Other roles of calcium in a ventricular cardiomyocyte.
Second, calcium also provides feedback to many of the ion channels that are used for

generating electrical currents of the cardiac action potential. While the functional implications of
these feedback systems have been the subject of extensive investigation, the mechanistic details
and physiological consequences are widely debated and largely unknown.
Third, changes in intracellular [Ca2+] can exert an influence on protein function through
post translational modification. Ca2+-sensitive enzymes such as calmodulin dependent kinase
2

(CaMKII) and the calmodulin enhanced phosphatase calcineurin, modify a myriad of proteins.
Despite extensive cellular and physiological characterization, the mechanisms underlying target
protein selection as well as post translational functional modification are insufficiently described,
and thus present knowledge gaps that limit our ability to connect atomic resolution structure with
cellular and physiological outcomes 2.
For my thesis, I have explored the relevant literature surrounding calcineurin structure
and function in ventricular cardiomyocytes. In this thesis, I highlight the seminal contributions
that have shaped our current understanding of calcineurin cardiac function in health and disease.
With the recent identification of mutations in the calcium sensing protein calmodulin, I seek to
understand if there are unique functions of calcineurin in a cardiomyocyte that could render the
heart susceptible to calmodulinopathy disease.

3

CHAPTER II
A REVIEW OF CALCINEURIN BIOPHYSICS WITH IMPLICATIONS IN CELLUAR
PHYSIOLOGY
2.1

Identification and nomenclature of calcineurin.
Calcineurin (CaN) was initially identified by two independent research laboratories 3,4. In

1976, Wang et al. demonstrated that bovine brain cyclic nucleotide phosphodiesterase (likely
PKA and/or PKG) required a higher concentration of a “calcium regulated protein modulator”
(one of the original names for calmodulin) for activation compared to heart tissue. This was due
to the presence of an “inhibitory factor” (CaN) in the brain preparations that counteracted the
activation of the phosphodiesterase 4. Concurrently, in 1976 Antoniw et al. demonstrated that
two distinct enzymes dephosphorylated the independent subunits of phosphorylase kinase 3
(phosphorylase kinase activates glycogen phosphorylase to release glucose-1-phosphate from
glycogen 5). β phosphorylase kinase phosphatase is now known as Protein phosphatase 1
glycogen-associated regulatory subunit or protein phosphatase type-1 glycogen targeting subunit.
The α-phosphorylase kinase phosphatase (later discovered to be comprised of two similar
enzymes, one of these being CaN, see below) was shown to be an inhibitor of: cyclic nucleotide
phosphodiesterase 3,6, adenylate cyclase 7,8, turkey gizzard myosin light chain kinase 9,
erythrocyte calcium magnesium ATPase 10,11, and phosphorylase b kinase 12. While the
mechanisms were not explicitly identified; inhibition likely occurs by either: CaN outcompeting

4

and exhausting calmodulin (CaM) availability, and/or dephosphorylation of the enzyme
substrate.
In 1979 the name calcineurin was coined by Klee et al. due to the “inhibitory factor’s”
calcium binding properties and prevalence in the nervous system 9; though it took a few years
before the name was widely adopted. In 1981, Helmreich et al. renamed alpha phosphorylase
kinase phosphatase to protein phosphatase 2 13. Shortly after, Stewart et al. resolved Protein
Phosphatase 2 into two fractions (PP2A and PP2B). Both PP2A and PP2B (CaN) can
dephosphorylate the α and β subunits of phosphorylase kinase, however there are enzymatic
differences between these two proteins. PP2A has broad substrate specificity and
dephosphorylates the phosphorylase kinase α subunit more rapidly (4-5 fold) than the β subunit.
Conversely, PP2B has narrow substrate specificity, but also dephosphorylates the phosphorylase
kinase α subunit more rapidly (100 fold) compared to the β subunit 13.
2.2

Metal binding and calcineurin activity.
In 1982, Stewart et al. demonstrated that CaN (isolated from bovine neuronal tissue) has

high affinity (Kd ≤ 10-6 M) for calcium in the presence of physiological concentrations of other
divalent cations (i.e. Mg2+ and Mn2+). Moreover, 8-12% of maximal CaN activity can be
obtained by calcium saturation (~ pCa 5.8). An additional 10-fold increase in CaN activity was
observed for the same calcium titration in the presence of CaM 14. In 1984, two separate labs
investigated the activity of CaN in the presence of other divalent cations. Li and Chan
demonstrated that full activity of brain CaN requires Ca2+, CaM, and another divalent cation
(Mg2+, Mn2+, Co2+, or Ni2+) 15. Using a p-Nitrophenyl Phosphate (pNPP) assay Pallen and Wang
demonstrated that Ni2+ and Mn2+ can activate CaN in the absence of CaM, and addition of CaM
further enhanced this CaN activity. Other divalent cations (Co2+>> Ca2+> Sr2+, Ba2+) require the
5

presence of CaM to exert significant enhancement of CaN activity. Cu2+ is a better activator of
CaN in the absence, rather than the presence, of CaM. Moreover, Be2+, Cd2+, Fe2+, Mg2+, Al3+,
Fe3+ do not stimulate CaN activity in the absence or presence of CaM. Lastly, Zn2+ inhibits the
activation of CaN by other cations in both the absence and presence of CaM 16. In 2004, Ping et
al. investigated specific components of CaN in order to identify a mechanism for divalent cation
activity enhancement. Their results revealed that the mechanism of divalent cation CaN activity
enhancement is complex and likely involves several domains of calcineurin 17. It is worth noting
that an iron atom was found in the active site of the crystal structure determined by Kissinger et
al. in 1995 (reviewed below). The iron is utilized for hydrolytic cleavage of phosphate from CaN
substrates 18.
2.3

Kinetic descriptions of the calcium-calmodulin-calcineurin interaction.
A decade after identification, quantitative biophysical properties of CaN were reported.

In 1987, Hubbard and Klee provided insight into the CaM-CaN complex lifetime by determining
the association ( kon = 8.9 x 103 M-1 s-1) and dissociation (koff = 8.5 x 10-5 s-1) rates. Moreover,
they calculated a dissociation constant for the CaM-CaN interaction (Kd ≤ 0.1 nM). The
dissociation rate (koff) of the CaM-CaN complex was shown to be dependent on free calcium
concentration ([Ca2+]free). A half maximal koff was achieved at 700 nM [Ca2+] 19. This suggests
that CaN has potential to function as a cardiac modification protein on a beat-to-beat basis, as
this [Ca2+] would provide a maximal calcium-sensing ability in between diastolic (0.1 μM) and
systolic (1.0 μM) [Ca2+] (Kd defines the inflection point, which has the steepest slope i.e. the
most sensitive response within the sigmoidal calcium binding curve). In 2005, Quintana et al.
utilized stopped-flow fluorescence spectroscopy to determine the association and dissociation
rates of the full length CaN-CaM interaction in the presence of calcium (4.6 x 107 M-1 s-1, 1.2 x
6

10-3 s-1, and calculated Kd of 28 pM). Moreover, a dissociation rate for the isolated CaN A
subunit-CaM interaction in the presence of calcium was determined (2.6 x 10-4 s-1) 20. In 2009,
Kilka et al. reported CaN dephosphorylation activity (KM and kcat) NFAT, DARP-32, Elk-1,
Tau, and RII peptide by α, β, and γ calcineurin using 33P-labeled substrates 21. These results
indicate that substrate processing is likely the rate limiting step of the CaN dephosphorylation
process, as the rapid calcium-calmodulin kinetics occur on a much more rapid timescale.
2.4

Isoforms of calcineurin.
There are three isoforms of the CaN A subunit (CaN A) (α, β, and γ) 22,23and two

isoforms of the B subunit (CaN BI and CaN BII) 24. In the heart, the CaN A subunit isoforms (α
and β) can interact with CaN BI 24. The CaN Aγ isoform is predominantly found in the testis and
can interact with CaN BII 22,25,26. It is worth noting that early CaN studies likely characterized
the α isoform of CaN A due to its abundance in neuronal tissue, which was the primary source of
CaN before recombinant protein expression.
2.5

Autoinhibition of calcineurin activity.
In 1979 Klee et al. demonstrated that calcineurin was comprised of two polypeptide

chains (CaN A, MW = 61,000 Da and CaN B, MW = 15,000 Da) and these two subunits form a
1:1 heterodimer (Figure 2.1). The A subunit interacts with CaM in a calcium-dependent manner,
and the B subunit directly binds Ca2+ 9. In 1983, Manalan and Klee demonstrated that, similar to
other CaM-stimulated enzymes, CaN can be activated and rendered Ca2+-CaM independent by
limited proteolysis. Moreover, they found CaM can protect CaN from degradation in the
presence of Ca2+. Based on their tryptic digest data, Manalan and Klee concluded that CaN
contained a long intrinsically disordered region connected to a small-structured domain (Auto
7

Inhibitory Domain (AID)) that was required for blunting enzyme activity. This was the first
report of an autoinhibitory mechanism that described CaN auto-inhibition 27. Shortly after,
Aitken et al. posited the CaN B subunit shares structural similarity with the four Ca2+ binding
regions of CaM and troponin C based on sequence analysis and garners method of secondary
structure prediction 28,29.

Figure 2.1

Diagram illustrating the key components of the CaN heterodimer (developed from
PDB ID: 1AUI 18). CaN A shown in salmon, CaN B shown in blue, AutoInhibitory Domain (AID), Calmodulin-Binding Region (CMBR). Due to the
disordered nature of the regulatory domain, this region has been represented by a
line and boxes for the distal helix and CMBR. Zn and Fe are located at the active
site for dephosphorylation of CaN substrates. The myristoylation site located at the
N-terminal region of the CaN B subunit is cleaved so the two CaN subunits can
form a heterodimer 30. Ca2+ binding to the CaN B subunit can evoke a small
enhancement of enzymatic activity in the absence of CaM. Ca2+−CaM−CaN
interaction enriches CMBR α-helical content resulting in translocation of the
autoinhibitory domain which leads to enhancement of CaN activity 31.

8

2.6

Enhancement of calcineurin activity.
CaN activity may be modified by several mechanisms. In 1994, Stemmer and Klee

demonstrated that CaN B and CaM activate the phosphatase by different yet complementary
mechanisms 31. In the absence of CaM, Ca2+ can stimulate a small but significant level of CaN
activity. At less than 10 nM [Ca2+], isolated CaN is inactive; while at approximately 500 nM
[Ca2+], 10% of maximal activation is achieved. CaM binding in the presence of Ca2+ further
stimulates CaN activity an additional 10-fold. Intriguingly, Ca2+ binding to CaN B is a
prerequisite for CaM enhancement of CaN activity. Stemmer et al. also posited that CaN B and
CaM play two different roles in calcium stimulation of CaN activity. Ca2+ binding to CaM results
in the disruption of the CaN AID from the active site and an increase in Vmax. Ca2+ binding to
CaN B increases the affinity of CaN for its substrate 31.
In 2006, Ye et al. reported a crystal structure displaying a 2:2 stoichiometry between
calmodulin and a peptide corresponding to the calmodulin binding domain of calcineurin.
Notably, the protein construct used for crystallization was comprised of only 25 amino acids of
calcineurin (corresponding to the calmodulin binding site 32) covalently attached to calmodulin
by a 5-glycine linker 33. In 2008, Ye et al. repeated this investigation without the 5-glycine linker
and reported a nearly identical 2:2 stoichiometric structure 34. In 2014, Dunlap et al. also
reported an x-ray crystallography structure of the calmodulin-calcineurin interaction. The
stoichiometry of calmodulin binding to this construct (regulatory domain of the catalytic subunit
of calcineurin (residues 373-468)) revealed a 1:1 stoichiometry which was also confirmed by
time-resolved fluorescence and size exclusion chromatography 35.
In 2012, Rumi-Masante et al. directly demonstrated that the autoinhibitory domain of
calcineurin is connected to the main catalytic subunit by an intrinsically disordered region using
9

hydrogen-deuterium exchange mass spectrometry. Based on calmodulin’s interaction with this
region, the region has been referred to as the “regulatory domain” (Figure 2). Ca2+-CaM binding
to the regulatory domain enriches the alpha helical content resulting in subsequent enzyme
activation. This is strikingly similar to the activation mechanism of calmodulin dependent kinase
type II 36. Notably, CaM binding to CaN allosterically enriches alpha helical content of more
than 45 amino acids 37. This highlights CaM’s ability to transmit long range signals. In 2013,
Dunlap et al. confirmed these findings and further demonstrated that the Ca2+-CaM-CaN
interactions reduce the distance between the two termini of the regulatory domain 38.
In 2016, Cook and Creamer demonstrated that molecular crowding increases α-helical
melting temperature of the calcineurin distal helix by measuring its thermal denaturation using
circular dichroism. Correspondingly, they observed that molecular crowding enhanced enzyme
activity 39, as increasing the α-helical content of the regulatory domain likely facilitates
dislocation of the autoinhibitory domain. In 2017, Yadav et al. reported solution state NMR
resonance assignments of the regulatory domain of CaN. These chemical shift values were
consistent with the CaN regulatory domain containing a high percentage of disordered content.
In depth analysis revealed that a small amount of secondary-structure helical propensity may be
present in the CaN regulatory domain in the absence of Ca2+-CaM 40. In 2018, Sun et al.
proposed a mechanism of CaM enhancement of CaN activity. Specifically, they posited that
residues outside of the CaM binding region may contribute to CaN activation based on molecular
dynamics simulation data 41. The complete mechanistic details governing CaN enhancement by
Ca2+ and CaM are still the subject of active inquiry 41,42.

10

2.7

External inhibition of calcineurin activity.
Cyclosporin A (CsA) is commonly used to prevent rejection of transplanted organs

(kidney, heart, bone marrow, and liver) in humans. Prior to the early 1990s, the molecular
mechanism was largely unknown and therefore has been the subject of much investigation. Many
scientists also use CsA and Tacrolimus (a.k.a. FK506) to inhibit CaN activity in vivo. In 1989,
Kay et al. demonstrated that lymphocyte activation induced by Ca2+ ionophores alone are
completely suppressed by 0.1 nM FK506 43. In 1989, Tropschug et al. observed that cyclophilin
mediates cyclosporin A effect and posited that binding of cyclosporin A to cyclophilin lead to
the formation of a complex that interacts with an “unidentified cellular component” (later shown
to be CaN) 44. Shortly after, Randak et al. found that CsA treated cell lack an interaction between
“lymphocyte-specific factors” (later shown to be CaN and NFAT, see section 2.10) and the
interleukin-2 enhancer 45.
In 1991, Lin et al. demonstrated that FK506 exerts its inhibitory effect during early
events of T-cell activation in a manner indistinguishable from CsA. Moreover, the pathways
inhibited by FK506 and CsA required measurable rise in intracellular calcium concentration 46.
Concurrently, Friedman et al. and Liu et al. demonstrated that CsA-cyclophilin and FK506FKBP12 complexes directly bind to and inhibit calcineurin in vitro 47,48. Fruman et al. built upon
these findings and demonstrated that CsA and FK506 lead to abolished CaN activity within
Thymus (T)-cells 49. These studies were the first to report a common mechanism of CaN
inhibition. It is important to note that the cyclophilin and FKBP12 proteins have other roles in
cellular physiology 50 and these require further investigation.

11

2.7.1

Other mechanisms of calcineurin-NFAT inhibition.
CaN activity may be impaired by several mechanisms, such as modification of the active

site metal properties or the substrate binding interface. In 2001, Namgaladze et al. demonstrated
that superoxide can inhibit CaN activity by reducing Fe3+ at the active site. Moreover, they found
that nitric oxide can block superoxide’s ability to inhibit CaN activity 51. In 2004 Roehrl et al.
identified several small organic molecules that inhibit CaN’s ability to activate the Nuclear
Factor of Activated T-cells (NFAT) by directly acting on the CaN-NFAT interaction 52. This was
unique as the commonly used CsA-cyclophilin and FK506-FKBP12 complexes achieve CaN
inhibition by blocking the calcineurin active site 47,48. Roehrl’s innovative strategy achieved
inhibition of the CaN-NFAT pathway without inhibiting other known cellular functions of
CaN 52.
2.7.2

A structural basis of calcineurin inhibition and activity.
Shortly after the molecular mechanism of CsA and FK506 was identified, the structural

underpinnings of inhibition were described. In 1995, Griffith et al. determined a high-resolution
x-ray crystal structure (2.5 Å) of neuronal bovine CaN bound to FKBP12-FK506 complex. To
obtain a well diffracting crystal, samples were subjected to proteolysis for 3-4 days in order to
remove disordered regions of the protein complex. The resulting structure captured the wellstructured regions of the CaN A and B subunits interacting with the FKBP12-FK506 complex.
This revealed the structural details underlying FK506-calcineurin inhibition. In this structure, the
FKBP12-FK506 complex does not contact the phosphatase active site on CaN A. Instead, it was
posited that the FK506-FKBP12 complex inhibits dephosphorylation by sterically occluding
substrate approach to the active site 53.

12

In 1995, Kissinger et al. determined multiple high-resolution x-ray crystal structures; one
of full-length human CaN (2.1 Å) and a second of full-length human CaN bound to FKBP12FK506 (3.5 Å). SDS-PAGE electrophoresis indicated that the protein crystals contained intact
CaN without proteolytic degradation. In the absence of the FKBP12-FK506 complex, the CaN
autoinhibitory domain sterically occluded the Zn/Fe active site. The well-resolved structure
suggested a mechanism for CaN substrate dephosphorylation. Specifically, dephosphorylation
could occur by a catalytic nucleophilic attack on the substrate phosphate by a metal activated
water molecule (Figure 2.2) 18.
In 2005, Kang et al. demonstrated that several small molecules can allosterically achieve
inhibition of calcineurin-Nuclear Factor of Activated T-cells (NFAT) association through
interactions outside of the consensus NFAT binding site (see calcineurin substrate binding
section below)

54

. In 2014, Qian et al. produced a novel high affinity (Kd = 2.6 nM) inhibitor of

the calcineurin NFAT interaction and showed that this peptide prevented NFAT translocation to
the nucleus using confocal microscopy 55.

Figure 2.2

Chemical equation of dephosphorylation of a serine residue by an iron atom
located in the CaN-active site adapted from Kissinger et al. (1995). A water
molecule is deprotonated by the iron atom, followed by a hydrolysis reaction
between the deprotonated (activated) water molecule and phosphorylated serine
residue (phosphoserine). This reaction yields serine and phosphate. Threonine
substrates follow a similar mechanism of water activation and dephosphorylation
18
.
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2.8

Endogenous regulators of calcineurin activity.
In 2009 Mehta et al. demonstrated that the human protein RCAN (Regulator of

Calcineurin) can either stimulate or inhibit CaN activity. There are three types of RCAN proteins
(RCAN1, RCAN2, and RCAN3) 56. RCAN stimulation of CaN required Glycogen Synthase
Kinase 3 (GSK-3) and the E3 ubiquitin ligase SCFCdc4. RCAN inhibition of CaN requires a
conserved calcineurin docking site (PxIxIT-like amino acid motif, described below). Moreover,
Glycogen Synthase Kinase 3 (GSK-3) and the E3 ubiquitin ligase SCFCdc4 were required for
calcineurin stimulation by RCAN 56. In 2009, Mulero et al. developed an in vitro highthroughput fluorescence polarization assay that utilizes an RCAN1 peptide for identifying
molecules that have immunosuppressant potential 57. In 2015, Kim et al. demonstrated that
protein kinase A indirectly inhibits CaN activity through RCAN1 using an NFAT luciferase
assay 58. Recently, Li et al. utilized a combination of structural, biophysical, and biochemical
techniques to describe RCAN1 inhibition of CaN activity. Specifically they found that RCAN1CaN inhibition occurs by multiple mechanisms: block of substrate recruitment sites and block of
the CaN active site 59.
In 1998, two independent laboratories identified an endogenous inhibitor of CaN. They
named the inhibitory protein calcineurin inhibitor (cain) and calcineurin binding protein 1 (Cabin
1). Sun et al. demonstrated that the CaN-cain/Cabin 1 interaction is dependent on protein kinase
C (PKC) and [Ca2+]. Specifically, they demonstrate that PKC and Ca2+ lead to
hyperphosphorylation of cain/Cabin 1. Furthermore, they observe that in the presence of a Ca2+
ionophore (ionomycin) and a PKC activator (PMA) CaN-dependent luciferase activity is almost
completely abolished 60. Concurrently, in 1998 Lai et al. demonstrated that cain/Cabin 1
noncompetitively inhibits CaN 61.
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2.9

Calcineurin substrate binding.
In 1982, Aitken et al. demonstrated that the N-terminus of the CaN B subunit contains a

myristoyl group 30. It is now known that myristoylation is widely utilized by many proteins for
membrane targeting 62. It remains to be determined if and how myristoylation influences or alters
the localization and/or substrate specificity of CaN. Localization of CaN to specific cellular
compartments could influence substrate selection. In 1994, Donella-Deana et al. demonstrated
(using small 6-32 amino acid peptides) that the sequence surrounding the substrate’s phosphate
does not always provide a clear signature for CaN activity 63.
2.9.1

Calcineurin binding region 1 (CNBR1) and the PxIxIT motif.
Over the past several decades, there has been a growing interest in CaN substrate

recognition. Thus far, two binding motifs have been identified. In 2004, Li et al. demonstrated
that several CaN targets (such as NFAT) utilize a common amino acid sequence for interaction,
the PxIxIT motif (also termed CaN Binding Region 1 (CNBR1) in 1998 64) 65. In 2007, Roy et al.
found that CaN binds with varying weak affinities to small peptides containing variations of the
PxIxIT motif. CaN, like other signaling enzymes, does not typically form stable complexes with
substrates. Intriguingly, weak CaN-substrate affinity conflicts with achieving selective target
protein post-translational modification 66.
In 2007, Li et al. provided a structural characterization that yielded insight into the
molecular requirements of CaN-PxIxIT motif interactions. An x-ray crystal structure of CaN
bound to a 14 amino acid peptide containing the PVIVIT sequence provided an atomic resolution
description of a CaN-substrate interaction and revealed the important side chains used for
binding. Alterations to the substrate amino acids significantly impaired CaN binding in vitro
which confirmed the observed crystal contacts. Additionally, this investigation found that the
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PVIVIT sequence generated the strongest of the series of PxIxIT interaction affinities. Lastly,
they reported that substrate affinity influenced the response of CaN to [Ca2+]67. This is
reminiscent of Ca2+-calmodulin binding affinity being tuned by substrate interaction 68.
2.9.2

Calcineurin binding region 2 (CNBR2) and the LxVP motif.
In addition to the PxIxIT motif, CaN utilizes a second binding motif that differs in key

binding properties from the PxIxIT motif. In 1999, Liu et al. identified a second binding region
for CaN-NFAT interaction (CaN Binding Region 2 (CNBR2)) using a GST-pulldown assay with
western blot analysis 69. Concurrently, Park et al. also reported a second binding site for
calcineurin in NFAT using a Secreted Alkaline Phosphatase (SEAP) assay 70. Soon after, Liu et
al. demonstrated that a shorter 16 residue peptide (Pep3 derived from CNBR2) was responsible
for the CNBR2 interaction 71. In 2006, Martı´nez-Martı´nez et al. provided a detailed
comparative analysis of CaN binding activity between PxIxIT and CNBR2 (now known as the
LxVP docking site). Consistent with data from Liu et al. (1999), Park et al. (2000), and Liu et al.
(2001), Martı´nez-Martı´nez et al. demonstrated that the NFATc1 LxVP motif binds CaN more
efficiently than PxIxIT motifs 72. It is important to note that these investigations utilized NFAT
binding sites. Further investigation is required to delineate if other CaN substrates have PxIxIT
and/or LxVP binding preference.
2.10

An overview of calcineurin function in cardiac physiology.
The most prominent and well-recognized CaN signaling pathway is attributed to the

activation of nuclear factor of activated T cells (NFAT). While not the focus of this review, a
brief description of the CaN-NFAT interaction has been provided to understand many of the
investigations that are focused on the roles of CaN in cellular functions. Dephosphorylation of
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cytosolic NFAT (NFATc) facilitates translocation of the CaN-NFATc complex to the nucleus,
which promotes synthesis of nuclear NFAT (NFATN) protein 73. An interaction between NFATC
and NFATN proteins lead to production of interleukin-2 (IL-2) (cytokine that is used for an
immune response). For a focused review of CaN’s role in NFAT signaling, see Hogan 2017 74.
2.10.1

Calcineurin is essential for cardiac development, cardiomyocyte stress response,
and cardiac physiology.
CaN has a prominent role in cardiac development. In 2010, Maillet et al. demonstrated

that cardiac-specific deletion of CaN was lethal for mice one day after birth. Specifically, they
found defects in right ventricular development, reduced ventricular trabeculation septal defects,
and valvular overgrowth 75. CaN also appears to have a role in adult cardiac physiology. CaN
deletion (alpha myosin heavy chain Cre-expression dependence) reduced cardiac contractility,
increased incidence of arrhythmia, and reduced cardiac myocyte content 75. Moreover, in 2006,
Bukowska et al. demonstrated that CaN A (β isoform) was significantly upregulated in human
atrial tissue from patients with sinus rhythm and chronic persistent atrial fibrillation 76.
CaN has also been shown to have a variety of other roles in cardiomyocytes as well as other cell
types. Moreover, several lines of evidence suggest that hypertrophy impairs physiological CaNion channel regulation (discussed below). For a comprehensive overview of direct interactions
between CaN and cardiac proteins, see Table 2.3. Interestingly, CaN is also an effector for
several proapoptotic kinases such as Apoptosis Signaling Kinase 1 (ASK1) and c-Jun N-terminal
protein kinase (JNK1/2) 77–79. These kinases are important for physiological viability of cells.
ASK1 is an upstream promotor of apoptosis that activates in response to proapoptotic stimuli.
Upon dephosphorylation of ASK1 by CaN, ASK1 disassociates with 14-3-3 protein 80.
Downstream to this dephosphorylation event, a variety of other kinases are activated such as
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JNK1/2 81. At the end of this signaling cascade, apoptosis is induced. For a review of ASK1
signaling with insights on prolonged JNK activation, see Ogier et al. (2020) 82.
2.10.2

Calcineurin, cardiac ion channels, and ion pumps
Given data presented by Bukowska et al. 76 and Maillet et al. 75, I have surveyed the

literature to understand the potential of CaN regulating or modifying cardiac ion channels and
pumps. While many of the investigations have explored CaN-ion channel modification
relationships for systems outside of a cardiomyocyte, there are several lines of evidence that
suggest CaN-ion channel regulation contributes to cardiac physiology.
In 2011, Prasad and Inesi demonstrated that CaN A can alter production of SERCA 2
leading to changes in cytosolic [Ca2+]. Neonatal rat ventricular cardiomyocytes with silenced
genes for either the α or β isoform of CaN A displayed reduced SERCA 2 expression.
Application of thapsigargin (SERCA 2 inhibitor) rescued SERCA 2 expression (mRNA and
protein) and restored Ca2+ transport. Importantly, these effects were reproduced using ionomycin
in place of thapsigargin. This is consistent with a mechanism where an increase in diastolic Ca2+
activates CaN and restores SERCA 2 production. Additionally, there is evidence that CaN
influences production of other important cardiomyocyte proteins. Cardiomyocytes exposed to
CsA displayed lower mRNA content for phospholamban and Na+/Ca2+ exchanger 83.
CaN has been shown to modify the function of the cardiac L-type calcium channel in
excitable cells. This channel has a pivotal role in establishing the cytosolic [Ca2+] through the
calcium-induced-calcium-release mechanism. Changes in cytosolic [Ca2+] activate or inactivate
many calcium-sensitive proteins and enzymes within a cell. In 1997, Schuhmann et al. observed
that CaN alters the function of the L-type calcium channel in human umbilical vein smooth
muscle cells 84. Others have shown that CaN activity and ion channel function are correlated in
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diseased cardiomyocytes. In 2000, Saito et al. demonstrated that CaN and the L-type calcium
channel play a critical role in isoproterenol-induced apoptosis of rat cardiomyocytes 85. Further
investigation of the physiological CaN-L-type calcium channel relationship is required as the
molecular and cellular functions are likely different in a diseased or non-stressed state 86. Much
of the work surrounding CaN-L-type calcium channel modification relies on the CaN inhibitor
CsA, and conflicting results are obtained from several laboratories. For further descriptions of
these disparate results, the reader is referred to Wang et al., 2014 86.
The heart the Na+/K+ ATPase may also be modified by CaN. In renal tubule cells, Aperia
et al. demonstrated that stimulation of α-adrenergic receptors increased the activity of the Na+/K+
ATPase. Addition of FK506, a CaN inhibitor, was shown to blunt the effects of α-adrenergic
receptor stimulation to the Na+/K+ ATPase 87. The α1and β1 isoforms contained in proximal
convoluted tubules appear to be present in cardiomyocytes 88. This raises the possibility that CaN
may have a role in stimulating Na+/K+ ATPase activity in a cardiomyocyte.
An interaction between CaN and the ryanodine receptor (RyR2) has also been posited for
modulating RyR2 Ca2+ release. In 2000, Bandyopadhyay et al. demonstrated CaN
coimmunoprecipitates with RyR2 in a calcium-dependent manner 89. Intriguingly, the RyR2
amino acid sequence contains 5 LxVP motifs which suggests CaN may contribute to RyR2
regulation. Moreover, CaN inhibitors (CsA and FK506) can modify RyR2 function, as
Bandyopadhyay et al. report they can reduce the frequency of spark calcium release 89. This data
is further supported by Savoia et al. as they demonstrated in 2014 that application of a CaN
autoinhibitory peptide reduces RyR2 calcium release frequency in airway smooth muscle cells 90.
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2.10.3

Calcineurin can impart different effects to ion channel function.
It has been demonstrated that CaN is involved in the restoration of the resting membrane

potential by dephosphorylating the Na+/K+ ATPase, resulting in Na+ retention 87,91. Conversely,
dephosphorylation of L-type calcium channel by CaN reduces ion channel conduction. The
mechanistic details of this process are largely unknown 84,85. In the case of the RyR2, it has been
suggested that CaN anchors to the FKBP12 accessory protein associated to the receptor and then
inactivates RyR2 by dephosphorylation. To the best of our knowledge, there is one report of this
mechanism, and further investigation is required 89.
2.11

Calcineurin’s roles and contribution to cardiac disease.
An extensive number of investigations have demonstrated that improper CaN activity can

induce and/or contribute to heart disease. Inhibition or reduction of CaN activity is becoming an
attractive approach for intervention 92,93. Table 2.2 provides a comprehensive summary of CaN’s
roles in cardiac pathophysiology. In addition to seminal findings, below some of the less
appreciated mechanisms of CaN signaling are highlight. Lastly, CaN activity with consideration
for hormone signaling and ion channel dysfunction is discuss.
2.11.1

Inhibition of calcineurin reduces cardiac hypertrophy.
One of the most prominent pathological outcomes related to CaN is cardiac hypertrophy

(thickening of the heart muscle). In 1998, Molkentin et al. demonstrated that addition of
phenylephrine or angiotensin II with constitutively active CaN or NFAT increased brain
natriuretic peptide (BNP) promoter activity (located in the heart). This increased BNP activity
was shown to be dependent on the presence of CaN, NFAT, and GATA4 (a transcription factor
involved in proper cardiac muscle development). This led to heart dilation and hypertrophy.
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Inhibition of CaN (CsA or FK506) prevented these effects 94. The role of CaN in cardiac
hypertrophy has also been investigated using other CaN inhibition strategies. In 2001, De Windt
et al. demonstrated that genetic inhibition of CaN by cain/cabin1 or the AKAP79 inhibitory
domain reduces cardiac hypertrophy in mouse models 95. In addition to preventing hypertrophy,
reducing CaN activity may also be advantageous for treating hypertrophic disease. In 2000,
Taigen et al. demonstrated that CaN activity is increased upon the addition of hypertrophic
stimuli (angiotensin II and phenylephrine) and application of CsA or FK506 rescued
cardiomyocytes from hypertrophy 96. This was unique as previous investigations from Molkentin
et al. had explored the effects of overactive CaN without consideration for variable CaN
activity 94.
While NFAT is the predominant mechanism identified for generating hypertrophy, there
are many proteins that can trigger this process. Moreover, CaN modification can have different
functional consequences in physiological and diseased states. In 2002, Sah et al. demonstrated
that overexpression of the KV4.2 N-terminus increased CaN activity and heart to body weight
ratio (changes in heart to body weight ratio are often attributed to cardiac dilation and/or
hypertrophy). Addition of Verapamil (L-type calcium channel inhibitor that reduces cytosolic
Ca2+ concentration 97) reduced the heart to body weight ratio. CaN’s contribution to the
phenotype was verified by application of CsA which removed the effects. Neither CsA nor
verapamil altered heart to body weight ratio in wild-type mice, suggesting that physiological
heart to body weight ratio is not reliant on CaN activity 98.
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2.11.2

Constitutively active CaN or NFAT can adversely affect ion channels and cardiac
function.
In 2001, Yatani et al. demonstrated that models of constitutively active CaN exhibit

enhanced L-Type calcium channel conduction. This led to cardiac hypertrophy and heart failure
99

. The mechanisms for this process remain to be elucidated, as CaN inhibitors such as CsA have

yielded disparate results 86. Under disease conditions, there is also evidence that CaN can modify
potassium channels. In 2006, Gong et al. demonstrated that excessive CaN activity
(constitutively active CaN) increases KV4.2 channel density through interactions with the KV4.2
gene. Addition of cain/Cabin 1 removed this effect 100. Interestingly, contrary effects have been
observed in other investigations, where hypertrophy impaired CaN-KV4.2 regulation.
Specifically, Zobel et al. observed that stimulation of CaN (phenylephrine) resulted in a
decreased KV4.2 current density 101. This was subsequently supported by Panama et al. who
demonstrated that CaN inhibition (via cain) can reduce mRNA of KChIP2 and Kv4.2 and the
combination of phenylephrine/propranolol exacerbated this effect 102. Further investigation is
required to understand how excessive CaN activity imparts different effects to KV4.2 channel
density.
CaN also modifies the production of other cardiac ion channel proteins. In 2006,
Kuwahara et al. demonstrated that activation of CaN in a pressure-overloaded system can
upregulate transient receptor potential proteins (TRPC6) in mouse and failing human hearts 103. It
has also been reported that CaN can form a complex with IP3R or RyR receptors through
interactions with FKBP12. Moreover, inhibition of CaN with CsA alters the Ca2+ flux produced
by ligand (IP3) activation of the ion channel 104.
In 2002, Petrashevskaya et al. demonstrated that constitutively active CaN or NFAT can
create several adverse physiological effects. Critical modifications such as increased action
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potential duration, decreased heart rate, and decreased β- adrenergic stimulation have been
observed 105. Moreover, De Windt et al. demonstrated that genetic inhibition of CaN
(overexpression of cain/Cabin 1 or the AKAP79 inhibitory domain) reduced isoproterenol
induced hypertrophy 95. Lastly, excessive inhibition of CaN during transaortic constriction leads
to modification of the function of several key proteins involved in cardiac calcium cycling
(phospholamban, RyR2, SERCA2a, and NCX) and promotes an increase in left ventricular end
diastolic pressure and myocardial stiffness 106. Given the abundance of ion channel targets that
are modified by CaMKII, under disease conditions (hypertrophic and constitutively active
CaMKII), it has been demonstrated that CaMKII can phosphorylate CaN (S197) leading to
reduced CaN activity 107. Further work is required to understand the relationships between
CaMKII and CaN function under physiological conditions.
2.11.3

CaN may also protect cardiomyocytes from DNA-damage-induced apoptosis.
CaN activity stimulated by phenylephrine protected cardiomyocytes from staurosporine

and 2-deoxyglucose induced cell death 108. This appears to conflict with other reports that have
implicated CaN in facilitating apoptosis 77–79. These investigations interrogate CaN using
different adrenergic pathways (phenylephrine = α-adrenergic stimulation, isoproterenol = βadrenergic stimulation). It is possible that similar to health and diseased states, the different
adrenergic pathways may utilize CaN activity uniquely. For a depiction of the α-adrenergic
stimulation pathway that results in pathophysiological hypertrophy, the reader is referred to
Cotecchia et al., 2015 (Figure 1) 109.
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2.11.4

Hormonal connections to calcineurin.
Hormone signaling is an important modifier of cardiac physiology. Of the several

hormones involved in regulating cellular homeostasis 110, estrogen has been demonstrated to
modify CaN signaling in pathological T cells, neuronal cells, and heart cells. Mechanisms
include estrogen receptor stimulation, alteration of CaN mRNA levels, and alterations to CaN
compartmentalization or localization. For a more in-depth review of hormonal regulation of the
heart, see Gordan et al., 2015 111.
With recent reports identifying estrogen modification of CaN in cardiomyocytes 112,113,
estrogen-CaN findings in T-cells are summarized as this may shed light on estrogen-CaN
cardiomyocyte signaling. In 1998, Rider et al. revealed that estrogen can alter the levels of CaN
mRNA in human female lupus T cells. The effects were found to be dose- and time-dependent
114

. In 2000, Rider et al. also demonstrated that the estrogen receptor can impart gender-specific

effects. Blocking female estrogen receptors (ICI 182,780) inhibited an increase in CaN mRNA
and CaN activity in female patients. Moreover, this effect was not observed in male patient T
cells 115, indicating that CaN has gender-specific physiological and diseased contributions. In
2008, Don Yi and Simpkins observed that in primary cortical neurons, glutamate (glutamateinduced apoptosis) decreases CaN and PP2A activity. Moreover, 17β-estradiol dampened
glutamate’s ability to alter CaN activity 116.
In 2008, Pedram et al. used a cardiac fibrosis model (angiotensin II-induced) to
demonstrate that 17β-estradiol indirectly inhibits CaN and prevents angiotensin II-induced
fibrosis. Specifically, knockout of the estrogen receptor (β isoform) impaired 17β-estradiol’s
ability to reduce angiotensin II enhancement of CaN activity. This data confirmed that the
estrogen receptor β isoform is required for estrogen reduction of CaN activity as well as
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prevention or rescue of cardiac hypertrophy and fibrosis. Moreover, RCAN1 protein expression
was found to be stimulated by 17β-estradiol 117, hinting at a possible mechanism for estrogenmediated CaN inhibition in a cardiomyocyte. In 2009, Donaldson et al. demonstrated that
estrogen hinders the rise in CaN A subunit expression that is induced by transaortic constriction
or phenylephrine. Based on this data, they posit that 17β-estradiol and estrogen receptors reduce
pressure overload cardiac hypertrophy by increasing CaN A degradation 118. Further work is
required to delineate the molecular and cellular mechanisms that underly hormonal CaN
regulation in cardiomyocytes.
2.12

There is still much work to be done.
While cellular and physiological descriptions of CaN function have been well described,

there are several knowledge gaps that limit our understanding of CaN’s role in cardiac
physiology and disease (Table 2.3). It will be of significant interest to characterize biophysical
details of CaN complexes. Quantitative descriptions such as kinetic on and off rates, binding
energies, and thermal stability of the CaN-substrate interactions will provide further insight into
CaN-mediated signaling pathways. Elucidation of these properties will illuminate potential
therapeutic targets and novel strategies for small molecule modification and intervention
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Table 2.1

Roles of calcineurin in cardiac physiology

Ref

Cellular
Function

Conclusion

Conditional
Effect

Mouse
Line

73

Adaptive
response

Jurkat cells

CsA and FK506 block NFAT
translocation

No stimulants
required

N/A

87

Adaptive
response

Jurkat cell

α-adrenergic stimulation → CaN
dephosphorylates Na+/K+ ATPase →
↑Na+/K+ ATPase activity

No stimulants
required

N/A

119

Apoptosis

BHK-21

CaN transfected cells + 4hr serum deprivation + calcium
ionophore = 60% apoptosis

CaN plays an important role in
mediating upstream events in calcium
activated cell death

+Ca2+ and growth factors

N/A

120

Adaptive
response

Jurkat cell

Indirect evidence suggests CaN + PMA = inactive IκB
via unknown kinase

CaN activation → inactivated IκB =
activate NF-κB

No stimulants
required

N/A

77

Adaptive
response

B lymphocytes

>5min @ 200-400 nM [Ca2+]i = activation NFATc
alone
>2min @ 1 µM [Ca2+]i = IκB degradation or JNK1 +
PO4

Amplitude and duration of [Ca2+]i =
activation of NFAT, NF-κB, or c-Jun
N-terminal kinase

No stimulants
required

N/A

121

Adaptive
response

Jurkat cells and
dominant
negative NFAT
Tg mouse model

dominant negative NFAT = ↓expression of IL-2 protein
Overexpression of CaN = restored IL-2 expression

NFAT = critical component of
signaling pathway that regulates IL-2
expression

No stimulants
required

B10.BR
/SGSNJ

89

Adaptive
response

Rat ventricular
CM

+Ca2+ = RyR2-CaN coimmunoprecipitation
+20 mM EGTA = no interaction
CaN inhibitors inhibit RyR2 Ca2+ release in CM

CaN-RyR2 interaction may modulate
calcium release in rat hearts

No stimulants
required

Sprague
Dawley

System

Results
NFATc translocates → nucleus and + newly synthesized
NFATN;
CsA and FK506 block translocation of NFATc without
altering synthesis of NFATN
synergistic activation of α1-α2 adrenergic receptors →
↑ Na+/K+ ATPase activity
CaN inhibitors abolish this ATPase enhancement
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Table 2.1 Roles of calcineurin in cardiac physiology (Continued)
Ref

122

Cellular
Function

Differentiation

85

Apoptosis

78

Adaptive
response

System

Results

Conclusion

Conditional
Effect

Mouse
Line

skeletal muscle
cells (C2C12
and Sol8)

+CaN or +NFATc3 → ↑MyoD → myogenesis
CaN inhibitor (CAIN) blocks differentiation

CaN signaling contributes to initial
myogenic myocyte differentiation
through NFATc3 dependent
mechanism

No stimulants
required

N/A

Isoproterenol induces apoptosis
CaV1.2 blocker (1 μM nifedipine) inhibit apoptosis
CsA and FK506 inhibit apoptosis

CaN and LTCC play a critical role in
iso-induced apoptosis of rat CM

Isoproterenol

Wistar

constitutively active CaN = ↑MAKP1 expression and
p38-MAPK inactivation in CM

CaN indirectly inactivates p38
MAPK
CaN + MEK1, MKK6, or MKK7 =
↑MKP-1 protein levels

Phenylephrine

Harlan
Sprague
Dawley

Ionomycin induces limb buds in mouse embryos
CsA → ↓cartilage development (both +/- ionomycin)
+ ionomycin → dephosphorylated NFAT4 = activated
NFAT4

CaN/NFAT4 activates bone
morphogenetic protein expression →
chondrogenesis (cartilage formation)

Ionomycin

N/A

cultured CM
from 1-day
Wistar rats and
dominant
negative CaN
Tg mice
Neonatal rat CM
primary cultures
10T12/2
fibroblasts and
COS-7 cells

123

Differentiation

chonrogenic
cells
(RCJ3.1C5.18)

79

Apoptosis

neonatal rat CM
with Adenovirus
modification

CaN dephosphorylates ASK1 = dissociation from 14-3-3
protein → activates ASK1
CaN and ASK1 cooperatively regulate CM apoptosis

CaN and ASK1 contribute to a
feedback regulatory mechanism
involved with signaling CM apoptosis

No stimulants
required

Sprague
Dawley

Apoptosis

CaNβ double
knockout mouse
model

Removal of CaNβ → ↑spontaneous T-cell apoptosis
IL-7 and/or IL-15 treatment ↓spontaneous T-cell
apoptosis
Constitutively active CaN → ↑Bcl-2 reporter activity

CaN → ↑B-cell lymphoma
expression
↑[CaNβ] → restored Bcl-2 protein
expression = ↑T-cell survival

No stimulants
required

C57BL/
6

124
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Table 2.1 Roles of calcineurin in cardiac physiology (Continued)
Ref

125

126

Cellular
Function

Growth

Adaptive
response

System
neonatal rat
ventricular
myocytes
PS120
Bovine
pulmonary atrial
endothelial cells
Human
pulmonary atrial
endothelial cells
HEK-tsA201

Results

Conclusion

Conditional
Effect

Mouse
Line

Na+/H+ Exchanger 1 (NHE1) interacts with CaN
NHE1 → activated CaN → NFAT translocates nucleus

NHE1 activity → ↑local pH → ↑CaN
activity → NFAT signaling →
cardiomyocyte enlargement
(hypertrophy)

Overexpressio
n of NHE1

Sprague
Dawley

CaN dephosphorylates MYPT1
MYPT1 interacts with CaN (pulldown)
Ka = 1.06*107
CsA + thrombin → sustains MYPT1 and myosin
phosphorylation → ↓endothelial electrical resistance

CaN dephosphorylation of cofilin and
Myosin Phosphatase → improve
endothelial barrier function (i.e.
increased electrical resistance)

Thrombin

Descriptions of the results and conclusions of relevant literature investigating the roles of calcineurin in cardiac physiology.
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Table 2.2
Ref

94

96

127

Roles of calcineurin in cardiac disease physiology
Conditional
requirement

System

Animal Model

Rat

Tg expression of
constitutively active
CaN
Tg expression of
constitutively active
NFAT3 (nuclear)

Angiotensin II
or
Phenylephrine

Rat

Neonatal Wistar-Kyoto

Angiotensin II,
Phenylephrine,
or 1% Fetal
Bovine Serum

Mouse

Sprague-Dawley mouse
model of Load-induce
hypertrophy

Abdominal
aortic banding
(AAB)

108

Rat and
mouse

95

Mouse

Sprague-Dawley rat
neonate
mouse model of
ischemia/reperfusion
mouse model of
constitutively active
CaN
Tg expression of
Cain/Cabin-1
Tg expression of
AKAP79 inhibitory
domain

Results
NFAT3 interacts with GATA4 (transcription factor)
CaN + GATA4 + NFAT3 activate (~150x) brain
natriuretic peptide promoter
CsA and FK506 → ↓induced hypertrophy
(Angiotensin II and Phenylephrine)
constitutively active CaN or NFAT → heart dilation
and hypertrophy
CaN (β-isoform) activity increased by hypertrophic
stiumli
↑expression of Cain or AKAP79 inhibitory domain
→ ↓stimulated enlargement of CM surface area
CsA and FK506 → ↓stimulated enlargement of CM
surface area
↑CaN activity → ↑coimmunoprecipitation of CaMCaN complex
CsA prevented AAB-induced ↑heart to body weight
ratios

Conclusion

Constitutively active CaN →
upregulated NFAT3 → cardiac
dilation and hypertrophy

↑CaN activity → ↑CM surface area
↓CaN activity can prevent ↑CM
surface area
In pressure overload hypertrophy:
CaN-CaM interaction is enhanced
CsA can ↓induction of hypertrophy
and/or partially reverse hypertrophy

DNA damage
inducing agent
(Saturosporine
or 2deoxyglucose)

constitutively active CaN = ↑ CM surface area +
protection from induced DNA damage
CaN (α-isoform) reduces DNA damage by multiple
mechanisms
Both NFAT3 and protein kinase B can contribute to
CaN driven protection from DNA damage

CaN can protect CM from apoptosis
in vitro and in vivo
CaN inhibition is not sufficient to
induce apoptosis in vivo

Isoproterenol

genetic inhibition of CaN activity in the heart reduces
load-induced hypertrophy

CaN is an important contributor to
pressure-overload hypertrophy
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Table 2.2 Roles of calcineurin in cardiac disease physiology (Continued)
Ref

99

128

98

105

129

Conditional
requirement

Results

Conclusion

Mouse

Tg expression of
constitutively active
CaN
Tg expression of CAIN
Tg expression of
AKAP79 inhibitory
domain

No stimulant
required

↑CaN activity → cardiac hypertrophy → quickly
progression to heart failure
↑CaN activity → altered LTCC conduction
altered LTCC due to changes Ca2+ signaling NOT
changes in LTCC gating

CaN induced hypertrophy is
associated with ↑LTCC activity

Mouse

C57BL/6
Tg removal of NFATc3
Tg removal of NFATc4

Abdominal
aortic banding
or Angiotensin
II

System

Animal Model

Mouse

Mouse
ventricle

Rat
ventricle

NFATc3 deletion → ↓pathological CaN induced
hypertrophy
NFATc4 deletion does not reduce pathological CaN
induced hypertrophy

mice lacking NFATc3 are partially
protected from cardiac hypertrophy
in response to CaN activation

Tg overexpression
Kv4.2 N-terminus

Kv4.2 Nterminus
overexpression

Reduced Ito → ↑CaN activity, ↑AP duration, and
↓SERCA2a expression
Overexpression of Kv4.2N-terminus leads to ↑heart
to body weight ratio
CsA or verapamil removed this effect and restored
SERCA2a expression

Tg expression of
constitutively active
CaN
Tg expression of
constitutively active
NFAT3 (nuclear)

Overexpression
of chronically
active CaN and
Isoproterenol

↑CaN activity or ↑NFAT3 = ↑ICa current density, ↑ICa
inactivation kinetics, ↑heart contractility, ↓Kv2.1
expression, ↑AP duration, ↓heart rate, and ↓βadrenergic stimulation

CaN overexpression causes
hyperdynamic cardiac remodeling

Sprague-Dawley

Phenylephrine
or Verapamil
and PKG overexpression

↑Phenylephrine → ↑LTCC activity → ↑NFATc3
translocation → ↑ transcriptional activity
↑Nitric Oxide → activation of PKG I →
↓phenylephrine effect
Nitric Oxide/cGMP diminish CaN induced CM size
increase

Nitric Oxide/cGMP activation of
PKG I inhibits hypertrophic CaNNFAT pathway in CM
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↓Ito → ↑Ca2+ cycling and

hypercontractility

Table 2.2 Roles of calcineurin in cardiac disease physiology (Continued)
Ref

130

131

132

100

System

Animal Model

Conditional
requirement

Results

Conclusion

Mouse

Tg expression of
dominant negative
JNK1/2
(C57BL/6 background,
FVB/N strain)

TAC

↓JNK1/2 activity = ↑heart to body weight ratio,
↑induced hypertrophy, and ↑CaN-NFAT signaling

dominant negative JNK → ↑CaNNFAT signaling → cardiac
hypertrophy

Mouse

Tg expression of
dominant negative
p38α
Tg expression of
dominant negative
MKK3
Tg expression of
dominant negative
MKK6

Aortic banding,
angiotensin II,
isoproterenol
infusion, or
phenylephrine
infusion

dnp38α, or dnMKK3, or dnMKK6 = ↑ heart to body
weight ratio, ↑heart dilation, ↑cross sectional area
Angiotensin II, phenylephrine, or isoproterenol
effects are enhanced in dominant negative animal
models with aortic banding
↓p38α activity + CaN A transient transfection = ↑
NFAT translocation to nucleus

dnp38α, or dnMKK3, or dnMKK6 →
↑CaN-NFAT translocation and
transcription

Mouse

Tg knockout of
guanylyl cyclase A
(C57BL/6 and 129SVj)

No stimulants
required

K.O. Guanylyl Cyclase A = ↑CaN activity, ↑NFATc3
translocation, ↑GATA4 DNA binding, ↑ANP and
BNP mRNA, ↑collagen I and III, and ↑Fibronectin
K.O. Guanylyl Cyclase A + FK506 → ↓observed
modifications

Disruption of guanylyl cyclase A
activates cardiac CaN-NFAT
pathway
FK506 → ↓fibrosis and hypertrophy

Rat

Overexpression of
constitutively active
CaN (Sprague-Dawley)

Overexpression
of CaN

↑CaN activity = ↑cell capacitance, ↑3H-leucine
uptake, ↑ KV4.2 mRNA, ↑KV4.2 current, and ↑chord
conductance
CAIN = removal of all enhancement effects

Constitutively active CaN →
↑cardiac KV4.2 current
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Table 2.2 Roles of calcineurin in cardiac disease physiology (Continued)
Ref

106

107

75

Conditional
requirement

Results

Conclusion

TAC

TAC + overexpression of ZAKI-4β = ↓PLB-PO4,
↓SERCA2a protein, ↓ NCX protein, ↓RyR2-PO4, and
↑Left ventricle end diastolic pressure → ↑myocardial
stiffness

In TAC mouse model: CaN
inhibition = ↓hypertrophy but does
not prevent diastolic dysfunction

Rat and
feline

Tg expression of
constitutively active
CaMKII
Tg expression of
dominant negative
CaMKII

No stimulants
required

↑CaMKII activity = ↓NFATc3 in nucleus, ↓fractional
shortening, ↑DNA damage
↑Ca2+ → ↑NFAT in nucleus
↑CaMKII activity → ↑NFAT-PO4
CaN inhibitors remove these effects

↑CaMKII activity→ phosphorylation
of CaN → ↓NFAT in nucleus

Mouse

Tg K.O. of CaN Bsubunit (C57BL/6
background)

No stimulants
required

Deletion of CaN B-subunit = fatal < 1 day after birth,
↓NFAT activity, ↓mRNA of ion-handling genes,
↓capillaries per myocyte, ↓active force generation,
and ↑CM size

CaN signaling is linked to control of
cardiac contractility, rhythm, and
expression of Ca2+ handling proteins

System

Animal Model

Mouse

Tg overexpression of
ZAKI-4β

Descriptions of the roles that calcineurin has in contributing to heart disease.
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Table 2.3

Calcineurin substrates

Substrate
Nuclear
Factor of
Activated Tcells 1-4
(NFAT1-4)
ATP
sensitive K+
channel
Myosin
Phosphatase
(MYPT1)
L-Type Ca2+
Channel
(LTCC)
Na+/K+
ATPase

KD
N/A

N/A

Molecular Effect
Dephosphorylation of NFATc
↑ Ca2+ = ↓ Kir6.1 current
Constitutively active CaN Aα= ↓ Kir6.1 current

Cellular Effect

Physiological Effect(s)

Ref.

Relocalization of CaM-CaNNFAT complex to nucleus →
bind to NFATN →
expression of interleukin

Initiation of inflammatory
immune response and/or
Cardiac Hypertrophy

61,94,1

N/A

N/A

27,133
–135

136,13
7

94
nM

CaN dephosphorylates 32P-MYPT1
MYPT1-CaN interaction supported by pulldown,
colocalization, and SPR experiments

N/A

N/A

126

N/A

Inside-out patch + CaN inhibits LTCC conduction

N/A

N/A

84,85

N/A

N/A

87

N/A

N/A

120

N/A

N/A

89

Apoptosis

N/A

79,80

N/A

N/A

138

N/A

IκB

N/A

RyR2

N/A

ASK1

N/A

Myopodin

N/A

Calsarcin1

N/A

+FK506 or CaN peptide inhibitor = no effect of
Oxymetazoline (Na+/K+ ATPase activator)
Constitutively active CaN + ionomycin = ↑NF-κB
reporter activity
Ca2+-dependent CaN binding to RyR2 → inactivation of
RyR2
CaN B dephosphorylates ASK1 (S967) → ASK1
dissociation from 14-3-3 protein → ASK1 activation
CaN dephosphorylates myopodin → hindered myopodin
binding to 14-3-3β
Prevention of myopodin binding to importin α
Calsarcin 1 binds to CaN A → formation of
trimer with α-actinin
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Localization of CaN to z-line
of cardiomyocyte

Inhibition of calcineurin in
hypertrophic signaling

139,140

Table 2.4

Calcineurin inhibitors

Inhibitor

Structure

Cyclosporin ACyclophillin A complex
(CsA-CyA)

Molecular Effect

Usage

Ref

CsA binding to cyclophilin A
→ Binding/inhibition of CaN

Clinical and
Experimental

48,141

FK506 binding to FKBP12 →
Binding/inhibition of CaN

Clinical and
Experimental

46,142

PDBID: 1CWA; Red = Cyclosporin A, Green = Cyclophillin A

Tacrolimus-FKBP12
complex (FK506FKBP)

PDBID: 1FKF; Red = FK506; Green = FKBP12
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Table 2.4 Calcineurin inhibitors (Continued)
Inhibitor

Structure

Calcineurin Inhibitor
(CAIN) protein/Cabin1

Molecular Effect

Usage

PKC hyperphosphorylation of
CAIN/Cabin1 →Inhibition of
CaN

Experimental

Posited that GCA/cGMP/PKG
signaling inhibits CaN

Experimental

Ref

60,61

PDBID: 1N6J; CABIN1 in complex with Myocyte-specific enhancer
factor 2B (MEF2B)
*MEF2B removed for clarity

Guanylyl Cyclase A

PDBID: 4NI2
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Table 2.4 Calcineurin inhibitors (Continued)
Inhibitor

Structure

Calmodulin Dependent
Kinase II (CAMKII)

Molecular Effect

Usage

Posited that rise in [Ca2+]i →
CaMKII activation →
phosphorylation/inhibition of
CaN

Experimental

Phosphorylation of RCAN1 →
binding/inhibition of CaN

Experimental

MuRF1 ubiquitinates CaN →
CaN degradation

Experimental

Ref

107

PDBID: 2UX0

Calcipressin 1
(RCAN1)

143

PDBID: 6UUQ; Orange = PO4, Green = Fe, Yellow = Zn
Muscle-specific RING
finger protein 1
(MuRF1)
PDBID: 4M3L

36
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